St. Cloud State University

theRepository at St. Cloud State
Culminating Projects in Biology

Department of Biology

5-2021

The Effects of Sodium Bicarbonate on Type One Diabetes
Development in Two Mouse Models
Jenna Nelson
St. Cloud State University, jmnelson4@go.stcloudstate.edu

Follow this and additional works at: https://repository.stcloudstate.edu/biol_etds

Recommended Citation
Nelson, Jenna, "The Effects of Sodium Bicarbonate on Type One Diabetes Development in Two Mouse
Models" (2021). Culminating Projects in Biology. 53.
https://repository.stcloudstate.edu/biol_etds/53

This Thesis is brought to you for free and open access by the Department of Biology at theRepository at St. Cloud
State. It has been accepted for inclusion in Culminating Projects in Biology by an authorized administrator of
theRepository at St. Cloud State. For more information, please contact tdsteman@stcloudstate.edu.

The Effects of Sodium Bicarbonate on Type One Diabetes Development in Two Mouse
Models

by
Jenna Nelson

A Thesis
Submitted to the Graduate Faculty of
St. Cloud State University
in Partial Fulfillment on the Requirements
for the Degree
Master of Science
In Biology: Cell and Molecular

May, 2021

Thesis Committee:
Marina Cetkovic-Cvrlje
Oladele Gazal
Bruce Jacobson

2
Abstract
Type one diabetes (T1D) is an inflammatory autoimmune disease in which T cells
coordinate and carry out an attack on insulin-producing beta cells in the pancreas. Currently, the
only treatment for T1D is life-long insulin injections, which cause great financial burden for T1D
patients and their families. Thus, it is crucial to explore cheaper preventative and treatment
options. Previous studies have shown that sodium bicarbonate (SB), an alkalinizing agent that is
typically used to treat indigestion, has the potential to reduce inflammation through its action on
macrophages. Thus, it was hypothesized that SB administration would decrease the incidence
and severity of T1D by its action on T cells in two mouse models, chemically (streptozotocin;
STZ)-induced T1D in C57BL/6J mice (STZ-B6 model) and spontaneously-developing T1D in
NOD/LtJ (NOD) mice. Seven-week-old B6 and nine-week-old NOD mice were administered
low-dose SB (20 mM) or high-dose SB (200 mM) via drinking water until the experimental
endpoints when B6 mice were 12-weeks-old and NOD mice were 12-weeks or 24-weeks-old. At
eight weeks of age, T1D was induced by STZ injections in B6 mice. Blood glucose and body
weight measurements were taken biweekly, in STZ-B6 groups, and weekly, in NOD groups for
the same duration as SB treatment administration. At experimental endpoints, mice were
euthanized, and the effects of SB on T cells were observed, by investigating the T cell
proliferation (splenocytes culture with an addition of a T cell mitogen), T cell
immunophenotypes (flow cytometry), and pro-inflammatory and anti-inflammatory cytokines
(flow cytometry). High dose SB significantly decreased T1D incidence in STZ-B6 mice and
glycemia levels in NOD mice at the early timepoint. A low-dose SB treatment, while exhibiting
trends, did not significantly decrease the development and glycemia levels in both murine T1D
models. Both high- and low-dose SB did not have prominent effects on T cell proliferation,
composition, or cytokines, besides the trends in lowering proliferation and proinflammatory
cytokines at the experimental endpoints. Overall, our results, while promising, do not support SB
as a major player in preventative efforts in the fight against T1D, highlighting the need for
further research in this area.
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I: Introduction
Diabetes is a metabolic disease that is characterized by chronic high blood glucose levels.
There are two main type of diabetes, type one diabetes (T1D) and type two diabetes (T2D). T1D
elicits high blood glucose through the irreversible destruction of insulin-producing beta cells in
the pancreas. T2D elicits high blood glucose levels through insulin receptor sensitivity, which
can be reversed. About 95% of patients are diagnosed with T2D and about 5% with T1D (Xu et
al., 2018). Diabetes can be considered an epidemic in many countries all over the world due to
the lack of available treatment, as well as increasing incidence and morbidity. Researchers have
repeatedly projected that diabetes prevalence in the US would increase at a fast rate, but they
were unaware of how fast. In 2001, a team of researchers used diabetes prevalence data as well
as demographical data to make projections of the future of diabetes in this country. They
projected a rise from 7.5 million individuals with diabetes in 1987 to >11 million in 2025 and to
almost 12 million by 2050 (Boyle et al., 2001). The prevalence of diabetes is over three times the
projected statistic for 2025 and it is only 2021. In 2018, 34.2 million people in the US had
diabetes (Centers for Disease Control [CDC], 2020). In 2014, 244 million people were living
with diabetes worldwide and in 2016, there were 1.6 million deaths directly caused by diabetes,
which was considered to be the seventh leading cause of death that year (World Health
Organization [WHO], 2020). Over the past decade, the incidence of diabetes has decreased,
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except in children under the age of 20 (CDC, 2020). In 2014-2015, just over 18,000 US children
were diagnosed with type 1 diabetes (T1D) while almost 6,000 were diagnosed with type 2
diabetes (T2D) (CDC, 2020). Although there has been an increase in the incidence of T1D and
T2D in children over the past two decades, T1D is often referred to as childhood or juvenile
diabetes and T2D affects mostly adults (CDC, 2020).
The only current treatment, once T1D is diagnosed, is insulin, which is expensive. To
lower the financial burden, in 2010 politicians and the Affordable Care Act (ACA) reduced the
percentage of out-of-pocket costs for T1D patients (Tseng et al., 2020). This price cut was
quickly negated by price gouging. From 2014 to 2019, the average annual insulin price in the
U.S. rose 55% from $3,819 to $5,917 (Tseng et at., 2020). Insulin is considered an essential
medication by the World Health Organization, which means it should be available at all times at
a price that individuals can afford (WHO, n.d.). Sadly, in the U.S., insulin is not sold at a price
that most T1D patients can afford, which may lead to drug underuse. Insulin rationing is when
T1D patients take a lower dose of insulin than needed to prolong the periods in which they
would need to purchase more insulin (Herkert et al., 2019). Patients that participate in insulin
rationing are more susceptible to hyperglycemic symptoms such as blindness, loss of limbs,
kidney failure, or even death (Herkert et at., 2019). When those affected by T1D need to choose
between taking the correct dosage of their insulin or buying groceries, a need for investigating
cheaper alternative intervention methods for T1D becomes clear.
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Type 1 Diabetes
T1D is an autoimmune disease that occurs when inflammatory T cells attack insulinproducing β-cells in the pancreas, which produces a halt in the body’s production of insulin,
leading to increased blood glucose levels (hyperglycemia). Early symptoms of T1D include
polydipsia (increased thirst), polyphagia (increased appetite), polyuria (increased urination),
weight loss, and fatigue (Kahanovitz, Sluss, & Russell, 2017). If untreated, ketoacidosis is likely
to occur, and more serious symptoms can follow, including cerebral edema, mental confusion,
unconsciousness, coma, and death (Kahanovitz et al., 2017). Long-term hyperglycemia can also
cause serious complications, including nephropathy, neuropathy, and retinopathy, some of which
could lead to amputation (McLaughlin et al., 2016). The only definitive answer that scientists
have come up with on T1D etiopathogenesis is that it is a matter of both genetics and the
environment (Knip & Simell, 2012). Though recent studies have been focused on environmental
triggers, geneticists have discovered a group of genes that may be responsible for disease
susceptibility including human leukocyte antigen (HLA), insulin gene, protein tyrosine
phosphatase non-receptor type 22 (PTPN22), interleukin-2 receptor alpha chain (IL2Ra), and
cytotoxic T-lymphocyte-associated protein 4 (CTLA4), among others (van Belle, Coppieters, &
von Herrath, 2011). Egro (2013) stated several hypotheses affirming that an increase in T1D
incidence could be an implication of increased hygiene over the past decades, viral infections,
vitamin D deficiency, and even a lack of breastfeeding. Without knowing the exact cause of
disease, the efforts that have been made toward the prevention of disease have been futile. Since
T1D depends on the over-reactivity of T cells, many preventative immunosuppressive
approaches are aimed at the destruction of these immune cells (Chatenoud, Warncke, & Ziegler,
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2012; Couri, Malmegrim, & Oliveira, 2018). However, these efforts did not provide the expected
results. Often the treatments had an overwhelming effect on the immune system, eliminating the
cells necessary to fight infections and tumors (Chatenoud et al., 2012; Couri et al., 2018).
Experimental Mouse Models
To develop and test drug treatments, while keeping the safety of human beings in mind, it
is pivotal for researchers to use alternative test subjects. Animal models are utilized in research
because of the similarities they share with humans in the context of physiology, anatomy,
immunology, and many other parameters. Choosing the ideal animal model for a specific
research project is crucial. For research in T1D, mice can be considered one of, if not the best
animal model. Mice are relatively inexpensive to purchase as well as maintain. They reproduce
at a rapid rate and share over 90% of their genome with humans (Masopust et al., 2017). There
are two common mouse models used in T1D research: female NOD/LtJ (NOD) mice, which
develop T1D spontaneously, and streptozotocin (STZ)-induced T1D in male C57BL/6J (B6)
mice (STZ-B6 model), in which T1D is induced chemically. NOD mice are the preferred model
because they develop the disease most similar to humans, spontaneously, and over time. The
downfall of using NOD mice is that they can take up to 40 weeks to develop diabetes (van Belle,
Taylor, & von Herrath, 2009). As stated above, B6 do not spontaneously develop T1D; they
require multiple low-dose intraperitoneal injections of STZ to induce disease (Cetkovic-Cvrlje,
Thinamany, & Bruner, 2017). STZ injections induce disease in B6 mice at a much faster rate
compared to the spontaneous T1D development in NOD model. The STZ-B6 model is utilized to
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exemplify how different environmental factors, such as pollutants or other toxins, may play a
part in disease development.
Streptozotocin
Streptozotocin (STZ) is a beta cell toxin, and it was initially used as an antineoplastic
drug against a rare form of cancer called metastatic pancreatic islet cell carcinoma (NCBI,
2020b). When administered as a single high dose, streptozotocin molecules are taken up by the
GLUT2 glucose transporter in the plasma membrane of a beta cell. Once in the cell, STZ begins
alkylating, which induces DNA fragmentation. The cell deploys efforts to repair the DNA but
fails, causing a depletion of ATP and other energy stores in the cell, and in turn necrosis
(Lenzen, 2008). This form of a massive high-dose STZ-induced beta cell death does not mimic a
typical autoimmune response to beta cells. Thus, to induce an autoimmune response to beta cells,
multiple low-doses of STZ need to be administered. When utilizing injections of low-doses,
similarly to the high dose injection, STZ molecules enter the cell through the GLUT2 glucose
transporter. Upon entering the cell, STZ triggers “low-grade” cell death and the consequential
leakage of autoantigens, such as glutamic acid decarboxylase and others, and inducing
sequentially a TH1-dependent inflammatory response (Van Belle et al., 2009). Another common
diabetogenic chemical is alloxan, which also enters the beta cells through the GLUT2 glucose
transporter. Alloxan acts by inhibiting glucokinase and induces toxic reactive oxygen species
production (Lenzen, 2008). Of the options for T1D chemical induction, low-dose STZ model is
the most plausible choice because it provides a unique way of mimicking the body’s
immunological response to beta cell damage.
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Immune Cells
The immune system can be divided into two branches: innate and adaptive. Both
branches work collaboratively to protect the body from infection and disease, but it is important
to note that each branch has a unique contribution to this process. The innate immune system
acts as an abatis against unfamiliar entities, such as bacteria and pathogens when they first enter
the body. The innate response is almost immediate and has perfect self and non-self recognition,
but it lacks in the areas of specificity and memory (Medzhitov & Janeway, 2000). Cells that aid
in the innate response include macrophages, natural killer cells, granulocytes, and several others.
The adaptive branch of immunity has a higher level of specificity and produces memory. Though
the adaptive response is superior in many ways, there are two major downfalls; self and non-self
recognition can be inconsistent, and the onset of the adaptive response takes several days. B and
T cells are the major cells of adaptive immunity. Since T1D is a T cell-mediated disease, T cells
play a major role in the process of autoimmune attack on beta cells. T1D development begins
when autoantigens are released by pancreatic beta cells and are taken up by an antigen presenting
cells (APC), such as macrophages or dendritic cells. The APC then processes the beta cells’
autoantigens and presents them to T cells that mistakenly recognize them as foreign and
differentiate into T helper 1 (Th1) cells. Th1 cells begin to release pro-inflammatory cytokines
that induce activation of T cytotoxic (Tc) cells and bring macrophages to begin direct beta cell
destruction. Cytokines released by the Th1 cells also aid in beta cell death indirectly through the
initiation of autoantibody production. Accumulation of immune cells, such as macrophages and
T cells, in the pancreatic Islets of Langerhans is called insulitis. It serves as the hallmark
histopathologic lesion of T1D.
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The cytokines that T cells release during initiation/continuation of autoimmune attack
play a significant role in the destruction of beta cells. T cells can be categorized based on the
cytokines and the markers they express; cytotoxic T cells (Tc), which express CD8 markers,
helper T cells (Th1, Th2, Th17), which express CD4 markers, and regulatory T cells (Treg),
which express CD4 and CD25 markers (Punt, Stranford, Jones, & Owen, 2019). Each cell type
can be further characterized by the cytokines they release. Contradictory to their name’s
“helpers”, Th1, Th2, and Th17 cells are not at all helpful, nor do they play the same roles in T1D
development. Th1 cells release the cytokines interleukin (IL)-2, interferon (IFN)-γ, and IL-6,
which are considered to be pathogenic, while Th2 cells release protective anti-inflammatory
cytokines, IL-4 and IL-10 (Punt et al., 2019). Th17 cells release IL-17, which is also considered
as pro-inflammatory cytokine, and destructive to beta cells. Treg cells do their implied job in
regulating the immune system and are said to have protective qualities during disease
development. Interestingly, Tc cells also release pro-inflammatory IFN- γ, as well tumor necrosis
factor (TNF)-α (Punt et al., 2019).
Sodium Bicarbonate
Sodium bicarbonate (SB), otherwise known as baking soda, is a monosodium salt
of carbonic acid, which functions as an alkylator (NCBI, 2020a). It has been used for decades to
treat minor health issues, including dyspepsia and reflux. It is also implemented in the treatment
of serious health complications, including metabolic acidosis, which may occur in severe renal
disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration,
extracorporeal circulation of blood, cardiac arrest, and severe primary lactic acidosis (NCBI,
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2020a). Several studies have suggested that SB treatment may have beneficial effects on other
inflammation related diseases, such as T1D.
Many physiological processes, including nerve conduction, muscle contraction and
cellular secretion, heavily rely on excitation from extracellular ions such as calcium, sodium, and
potassium (Katz, 1966). However, the effects of these ions were not studied in the context of
insulin production until 1968, at which time Hales, & Milner performed in vitro experiments on
pancreatic tissue from rabbits. Pancreata were incubated in bicarbonate-buffered salt solution and
insulin production was tested with the addition of several individual and combinations of ions. It
was concluded that insulin release was favored when Na+ ions entered the pancreatic beta cells
(Hales & Milner, 1968). Malaisse, Malaisse-Lagae, & Brisson (1971) performed in vitro
experiments on pancreatic tissue collected from rats to test the rate of glucose-induced insulin
secretion in the presence of several cations. This study concluded that alkali cations, such as Na+
could influence insulin secretion in beta cells (Malaisse, Malaisse-Lagea, & Brisson, 1971).
Thus, the addition of Na+ cations through SB treatment could potentially be having an effect of
insulin-producing beta cells, in which insulin production is prolonged. The mechanism behind
the prolonged insulin production is likely related to the sodium-pumps within the membranes of
beta cells.
Bicarbonate ions may also play an important role in the decreased glycemia levels and
T1D incidence observed in SB-treated mice. Metabolic alkalosis is a condition that occurs when
serum bicarbonate levels are increased in the body, which is caused by a loss H+ cations or a gain
in HCO3− anions, which, in turn, causes increased systemic pH (Singh, 2010). The effects of high
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and low pH environments have been previously studied in the context of T1D incidence. Sofi,
Gudi, Karumuthil-Melethil, Perez, Johnson, & Vasu, C. (2014) did several in vivo experiments
on the effects of acidic and neutral drinking water on T1D development in 9-week-old NOD
mice to test whether T1D is potentiated through consumption of acidic drinking water and
concluded that acidic (pH 3.0-3.2) drinking water did, in fact, significantly increase T1D
incidence (Sofi et al., 2014). They proposed that this increase was due to the ability of HCl to
induce a direct (IL-8-mediated) inflammatory response in the esophageal mucosa, which
indirectly initiated an inflammatory Th-1 response, with potentially increased levels of proinflammatory cytokines, IL-6 and TNF-α. These findings support the hypothesis that an alkaline
(high pH) environment may have beneficial effects in the context of T1D development.
Interestingly, a consequence of metabolic alkalosis is increased sodium retention, which, as
previously described, may have positive effects on insulin secretion (Eckstein & Corey, 2019).
There were several studies done between 2014 and 2018 that lead to the idea that SB
could play a role in inflammatory disorders. The first study, published in 2014, observed the
effects of SB on kidney function in patients with chronic kidney disease (CKD). This study
concluded that SB had the potential to slow the progression of CKD through alkalization and the
reduction of levels and/or effects of angiotensin II, endothelin, and aldosterone in the kidney
(Łoniewski & Wesson, 2014). Another study, published in 2015, adjudged that treatment with
anti-TNF-α drugs slowed kidney function loss in patients with CKD (Kim et al., 2015). Based on
this study, Ray et al. (2018) hypothesized that SB could be acting as an anti-inflammatory agent
in CKD patients. They studied macrophages in rats administered with 0.1M SB via drinking
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water and analyzed their spleens by flow cytometry. The results showed a reduction in M1
(inflammatory, TNF-α-producing) macrophages, and an increase in M2 (anti-inflammatory, IL10-producing) macrophages. Thus, they concluded that SB exhibited anti-inflammatory
properties, through its action on macrophages. One can assume that SB’s anti-inflammatory
effects on macrophages might also be observed on T cells. The Ray et al. study speculated about
SB's potential in the prevention of autoimmune diseases. However, SB effects has never been
tested in vivo in an experimental model of autoimmune disease. With T1D being a T cellmediated autoimmune disease, and a lack of knowledge on the effects of SB on T cells, further
research in this area is imperative.

II: Aim and Hypothesis
The aim of this study was to illuminate antidiabetic properties of SB using STZ-induced
and spontaneous T1D mouse models. Since T1D is a T cell-mediated disease, the effects of SB
treatment on T cells were closely examined. It was hypothesized that SB administration would
decrease the incidence and severity of T1D by its action on T cells in a STZ-B6 and NOD mouse
models.
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III: Experimental Timeline
B6 mice were divided into the three experimental groups (control, 20 mM SB, and 200
mM SB) at seven weeks of age (Day -7). Initial blood glucose and body weight measurements
were also taken at that time. At eight weeks of age (Day 0), STZ injections began. Starting at
nine weeks of age (Day 7), blood glucose and body weight measurements were taken biweekly
until the end of the experiment. On Day 28, mice were euthanized, and T cell-related analyses
were performed. T cell-related analyses provide insight on the function and composition of T
cells by performing proliferation assays, quantification of T cells by flow cytometry and a more
detailed look into T cell subpopulations/function by cytokine analysis.
NOD mice were divided into the three experimental groups at nine weeks of age (Week
9). At this time blood glucose and body weight measurements began and were taken weekly until
the end of the experiment. For NOD experiments, there were two experimental endpoints, an
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early endpoint, when mice were 14 weeks of age and a late timepoint, experimental endpoint,
when mice reached 23 or 24 weeks of age. At these timepoints mice were euthanized and cell
analyses were performed.

IV: Methods
Mice
C57BL/6J and NOD/LtJ breeding pairs were purchased from Jackson Laboratory in Bar
Harbor, ME for continued breeding at the St. Cloud State University Vivarium. All mice are
housed in NexGen Lo-Profile caging systems in temperature- and relative humidity- controlled
rooms with a twelve-hour light/dark cycle. Mice are allowed constant access to casein-based
phytoestrogen-free food (AIN-93G Rodent Diets, Research Diet, Inc., Harlan research
laboratories) and filtered water. When the breeding pairs produced offspring, and those offspring
reach sexual maturity (28-32 days of age) they were housed in separate-sexed cages until they
were selected for an experiment. Seven-week-old male STZ-B6 and nine-week-old female NOD
mice were used for experiments. During the duration of each experiment, mice were closely
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observed for fluctuations in behavior and/or health. St. Cloud State University Institutional
Animal Care and Use Committee approved all protocols/procedures (protocol #5-113).
Sodium Bicarbonate Preparation
200 mM and 20 mM concentrations of SB (Sigma-Aldrich) drinking water were prepared
by mixing SB powder with deionized water (Ray et al., 2018). The solutions were then
autoclaved along with non-treated, deionized (control) water. After autoclaving, the solutions
were placed on the lab bench and left to cool until they reached room temperature. The water
solutions were then distributed to the appropriate cages via glass bottles with rubber sips when
STZ-B6 mice were seven weeks old and NOD mice were nine weeks old. For the remainder of
the experiment, the water bottles and sips were changed weekly.
Type 1 Diabetes Induction by Streptozotocin Injections in B6 Mice
On five consecutive days, a low-dose of STZ was injected at 40 mg/kg/day,
intraperitoneally (i.p.), to control and SB-treated 8-week-old, male, STZ-B6 mice (CetkovicCvrlje et al., 2017). Prior to injections each day, 0.05 M sodium citrate buffer was prepared by
dissolving 147.1 mg sodium citrate (Sigma-Aldrich) in 10 mL of cold, deionized water. The pH
of the sodium citrate buffer was determined using a pH meter and adjusted using 1 M HCl and 1
M NaOH solutions until a pH of 4.5 was attained. STZ was then dissolved in the sodium citrate
buffer and vortexed. Injections were administered with a 1 mL syringe and a 26 G x 5/8 needle at
6.52 µL/g of mouse body weight (ter Veld et al., 2008). Due to the rapid denaturation rate of the
solution, the time to complete injections did not exceed 15 minutes. NOD mice did not receive
STZ injections, because they develop T1D spontaneously.
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Blood Glucose and Body Weight Measurements
To acquire a blood glucose measurement, a mouse was placed in a 50 mL Falcon tube
with predrilled breathing holes. The tail of the mouse was slid into a predrilled hole in the cap of
the Falcon tube, allowing for manipulation of the tail with the least of amount of discomfort for
the mouse. An Accu-Chek Aviva blood glucose meter strip was placed into the Accu-Chek
Aviva glucometer (Roche Diagnostics, Indianapolis, IN, USA). A lateral tail vein puncture was
then performed using a 26 G x 5/8 needle. This puncture produced a small drop of blood (~ 0.6
µL), which was placed onto the blood glucose meter strip. The glucometer displayed a digital
reading of the blood glucose level in mg glucose/dL. A mouse was considered diabetic after two
consecutive readings of ≥ 250 mg glucose/dL (Cetkovic-Cvrlje et al., 2017). A wet paper towel
was placed over the puncture wound and light pressure was applied to stop any excess bleeding.
Body weight measurements were collected by placing a plastic holding bin on a digital scale.
Each mouse was individually placed into the bin and the body weight (g) was digitally displayed.
Male STZ-B6 mouse glucose and body weight measurements were performed on the first day of
the experiment (day -7) and, biweekly, starting 7 days after the initial STZ injection, until the
experiment end. Female NOD mouse glucose and body weight measurements were obtained on
the first day of the experiment and once a week for the remainder of the experiment.
Euthanasia
Mice were euthanized via CO2 asphyxiation at the particular endpoints. The mice were
placed into an empty, clean 10-gallon plastic box. A stainless-steel lid, which is attached to a
CO2 tank by flexible polyvinyl tubing, was placed on top of the box. The CO2 tank was opened,
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allowing CO2 (at ≥ 200 psi) to fill the tank. The mice remained in the tank for at least 10
minutes; during this time, their heartbeats stopped, and the mice were considered deceased.
Preparation of a Spleen Single Cell Suspension
After euthanasia, spleens were aseptically harvested from SB-treated and control mice
and were mashed using the flat end of a 10 cc syringe plunger and a 70 mm nylon mesh strainer
(BD Falcon, USA) with the addition of phosphate-buffered salt solution (PBS, Sigma-Aldrich).
This process produced splenic single cell suspensions (SCS). The SCSs were put into a
centrifuge and spun for 5 minutes at 1200 rpm 4˚C. The supernatants were decanted, and the
pellets were resuspended in 0.75 mL of ACK lysis buffer (NH4Cl 8.29g/L, KHCO3 1.0g/L,
EDTA Na2· 2H2O 0.0375g/L; 18 Lonza Bio Whittaker, Walkersville, MD, USA) for one minute
to lyse all erythrocytes. 5 mL of PBS were added to the solution to stop the lysing process. The
SCSs were washed and centrifuged three more times using PBS to remove any remaining cell
debris and lysing buffer. In order to count cells, 10 µL of each SCS was mixed with 190 µL of
Trypan blue (Lonza BioWhittaker), which stains dead cells blue. 20 µl of the mixture was loaded
into a hemocytometer for cell counting with a light microscope at 10x magnification. Alive
(yellow) and dead (blue) cells were counted separately, allowing for detection of the total and
alive number of cells. It was important to identify the number of living cells in each sample
because living cell counts were used to determine the volume of each SCS used in the T cell
proliferation assays as well as in the samples analyzed by flow cytometry.
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T-cell Proliferation
Splenocytes from SB-treated and control mice were suspended in complete media (CM),
which contained RPMI-1640 medium, 1 U penicillin/ml, 100 µg streptomycin/ml and 10% fetal
calf serum (FCS) (all purchased from Sigma-Aldrich). The CM-suspended cells were cultured in
triplicates in a 96-well-plate at a concentration of 4x105 in a total volume of 100 µL along with
an entire row of CM only wells. Samples were cultured with and without the addition of 3
µg/mL Concanavalin A (ConA, Sigma-Aldrich), and left to incubate in the incubator (Thermo
Electron Corp. Forma Series II Water-Jacketed CO2 Incubator 3110) for 72 hours at 37˚C and
5% CO2. ConA is T cell mitogen, which means it is used to induce proliferation (mitosis) of T
cells (Dwyer & Johnson, 1981). After 72 hours of culture, 10 µl of Alamar blue (Invitrogen)
were added to each well, and the plate was incubated for an additional 4-6 hours. Optical
densities were then measured, at 570 nm, by an ELISA plate reader (GeneMate). Alamar blue is
a colorimetric assay that is commonly used to measure the reducing capacity of cells. It contains
a stain called resazurin, which changes color based on the amount of cellular reduction occurring
in the sample; the amount of living cells was directly proportional to the intensity of fluorescence
(O’Brien et al., 2000). To calculate the normalized level of T cell proliferation, the average
absorbance of the CM only row was subtracted from the average of each triplicate. Then, the
results obtained in T cell proliferation assays are presented either as a direct readout (OD levels)
or calculated as proliferation indexes. A proliferation index was obtained by dividing the average
of the normalized ConA stimulated wells by the average of the normalized non-stimulated wells.
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Immunophenotyping
Splenocytes were analyzed in order to detect particular types of immune cells
(immunophenotypes) by flow cytometry (Cetkovic-Cvrlje et al., 2016). Two aliquots of 1x106
splenocytes were obtained from the SCS of each mouse and were placed into appropriately
labeled polystyrene tubes. These aliquots were spun down via centrifugation for 5 minutes at
1200 rpm at 4°C. The supernatants were decanted, the polystyrene tubes were blotted to
withdraw excess buffer, and the pellets were resuspended in 1 mL of FACS buffer (0.1%NaN3,
1% FCS in PBS). To differentiate and quantify immune cell populations, each sample was
stained with a specific antibody mixture. Antibody mixtures were prepared by adding
fluorochrome-tagged antibodies to FACS buffer in a 1:100 ratio. After addition of the antibody
mixtures, the samples were incubated in the dark at 4˚C for 45 minutes, washed three times with
FACS buffer, and analyzed using a FACSCalibur (BD Biosciences) flow cytometer. The
antibodies against particular cell markers were purchased from BD Biosciences; these immune
cell markers and their associated fluorochromes can be found in Table 1. A minimum of 10,000
cells was acquired for each analysis. Immunophenotype analysis was performed using CellQuest
Prosoftware (BD Biosciences).
Table 1
Immune Cell Types Analyzed via Flow Cytometry
Cell Type

Cell Marker

Fluorochrome

T cell (all types)

CD3

PE

T-cytotoxic

CD8

FITC
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T-helper

CD4

PerCP

T-regulatory

CD4 & CD25

APC

B cell

CD45RB220

APC

Natural Killer Cell

CD335

FITC

Macrophage

CD11b

PerCP

Note. Cell types, cell markers, and antibody-associated fluorochromes that were used for flow
cytometry. The fluorochrome column displays abbreviations of the following fluorochromes:
peridinin chlorophyll-a protein (PerCP), fluorescein isothio-cyanate (FITC), allophycocyanin
(APC), and phycoerythrin (PE).

Cytokine Acquisition and Analysis
Splenocytes from the SCSs of SB-treated and control mice were suspended in CM and
cultured in a 24-well plate at a concentration of 2x106 in 500 µL. Half of the wells were cultured
with the addition of ConA, to stimulate cell growth, and the other with the addition of more CM,
creating a total volume of 1 mL/well. The samples were incubated for 48 hours at 37˚C and 5%
CO2. The plate was then centrifuged for 10 minutes at 1200 rpm at 4°C. The supernatants in each
well were collected and aliquoted into microcentrifuge tubes in triplicates (250 µL each). The
aliquots were labeled and stored at -80°C until they were analyzed. A CBA Mouse
Th1/Th2/Th17 cytokine kit (BD Biosciences, USA) was used to quantify the following
cytokines, IL-2, IL-4, IL-6, IL-10, IL-17, IFNγ, and TNFα in the collected samples. To begin the
analysis, lyophilized mouse standards were reconstituted in 2.0 mL of assay diluent and a serial
dilution was performed starting with a 1:2 dilution and ending with a 1:256 dilution. Capture
beads for each cytokine were then vortexed and mixed to make a single capture bead solution; 50
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µL of the single capture bead solution along with PE detection reagent was added to each mouse
sample. The samples were left in the dark to incubate at room temperature for two hours. The
samples were then washed and centrifuged with wash buffer, the supernatant was removed, and
the pellet was resuspended with 300 µL of wash buffer. Acquisition of samples was done using a
BD Biosciences FACSCalibur flow cytometer or a BD Biosciences Accuri C6 Plus flow
cytometer. Analysis of the data was performed via FCAP array software (Softflow, New
Brighton, MN, USA). Recently, The Immunology Laboratory obtained an Accuri C6 Plus flow
cytometer. Immunophenotyping and cytokine profiling experiments that were performed before
2021 were done so using the FACSCalibur flow cytometer (Figures 4, 9, 10, 14, 15, 17C, 21,
24C, and 24D). Immunophenotyping and cytokine profiling experiments preformed since the
start of 2021 were do so on the Accuri C6 Plus flow cytometer (Figures 5, 17D, 22, and 24D).
Statistical Analysis
For each of the statistical analyses, a p-value of < 0.05 was considered significant.
Differences in diabetes incidence among experimental groups was determined using a life-table
analysis, specifically looking at the log-rank test, using JMP Pro 14 statistical analysis software.
For blood glucose levels and body weight data, Microsoft Excel was used to run a one-way
analysis of variance with repeated measures, otherwise known as an ANOVA test. For
immunophenotyping, T cell proliferation, cell counts, and cell viability, a Student t test was
performed using Microsoft Excel.
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V: Results
1. Effects of 200 mM Sodium Bicarbonate Treatment in STZ-B6 mouse model
T1D Incidence and Glycemia Levels
Seven-week-old male B6 mice were randomly split into control and SB treatment groups.
At this time, each group began drinking non-treated or 200 mM SB-treated water. At eight weeks
of age, mice were administered five, low-dose (40 mg/kg), IP-injections of STZ to induce T1D.
Glucose measurements were recorded at day -7 before, and biweekly from day 7 to day 28 post
the first STZ injection. Mice were considered diabetic after two consecutive glucose readings of
≥250 mg/dL. SB treatment did significantly reduce the incidence of T1D (p=0.0444) (Figure
1A). Though no significance was observed, 200 mM SB-treated mice had lower glycemia levels
than control mice throughout the entire duration of the experiment (Figure 1B). At the end of
experimental period, there were 90% of diabetic mice in the control group versus 67% in SBtreated group (Nelson, Olson, Zaher, & Engelmann, 2020a; Nelson, Olson, Zaher, Engelmann, &
Cetkovic-Cvrlje, 2020b).

31
Figure 1
Diabetes Incidence and Glycemia in STZ-treated B6 Mice Treated with 200 mM SB
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Note. Diabetes incidence (A) and average glycemia (B) in STZ-treated B6 male mice treated
with 200 mM SB for five weeks and their respective controls. (A) Diabetes incidence presented
as the percentage of diabetes-free mice in control and SB treatment groups; *p<0.05 (B)
Glycemia measurements were taken at days -7, 7, 11, 14, 18, 21, 25, and 28 pre/post first STZ
injections. Data presented as average ± SEM.

32
Body Weight, Cell Counts, and Cell Viability
Body weight measurements were recorded, in grams, on the same days as glucose
measurements (day -7, 7, 11, 14, 18, 21, 25, 28 before and after the first STZ injection). There
was no significant difference observed in body weights between control and SB treatment
groups, insinuating the absence of SB toxicity in vivo (Figure 2A). On day 28 post the first STZ
injection, mice were sacrificed, spleens were harvested, and single cell suspensions were
prepared. The total number of splenocytes were counted via hemocytometer; cell viabilities were
calculated using the percentage of alive cells. There were no significant differences between
control and SB treatment groups when looking at cell counts and cell viability (Figures 2B and
2C), indicating that SB did not affect splenocyte viability. On the graphs showing cell counts and
viability, one can observe a lower number of analyzed mice in comparison to the original number
of mice put in the experiment. In several experiments, this was due to the technical difficulties
during the preparation of samples. However, in other experiments, such as long-term NOD
experiments, the lower number of mice was due to the number of mice that developed prominent
T1D symptoms before the experimental endpoint, in which case mice were euthanized to
minimize suffering. Out of 20 control and 18 SB-treated mice analyzed at the end time-point,
there were 16 (80%) and 13 (72%) diabetic mice, respectively (Figure 2B and 2C).
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Figure 2
Body Weights, Cell Counts, and Cell Viability in STZ-treated B6 Mice Treated with 200 mM SB
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Note. Average body weights (A), cell counts (B), and cell viability (C) in 200 mM SB-treated
and control STZ-B6 mice sacrificed at the experimental endpoint. (A) Body weight
measurements started on day -7 before the first STZ injection and lasted until the experimental
endpoint. Data presented as average ± SEM. (B) Cell counts were measured using the Trypan
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blue exclusion method. Data presented as average ± SEM. (C) Cell viability was calculated using
cell counts. Data presented as average ± SEM.

Immune Parameters
Following cell counting, the effects of 200 mM SB on several immune parameters at day
28 were assessed. These immune parameters included T cell proliferation levels and proliferation
indexes, immune cells subpopulations, and cytokine profiles, all of which were derived from
splenocytes.
Splenocytes were plated in triplicates with and without the presence of ConA, a T cell
mitogen. After 72 hours, the cells were stained with Alamar blue and analyzed via
spectrophotometry. There were no significant differences observed when comparing T cell
proliferation levels in control versus 200 mM SB treatment groups (Figure 3A). Proliferation
index was calculated by taking the average normalized stimulated optical density divided by the
average normalized non-stimulated optical density of both control and 200 mM SB-treated
groups. There was no difference between the control and SB treatment groups when comparing
proliferation indexes (Figure 3B). Out of all 12 control and 11 SB-treated mice analyzed in
proliferation essay, there were 10 (83%) and 8 (73%) diabetic mice, respectively (Figure 3B and
3C).
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Figure 3
Proliferation Levels and Proliferation Index in STZ-treated B6 Mice Treated with 200 mM SB
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Note. Proliferation levels (A) and proliferation index (B) in 200 mM SB-treated and control
STZ-B6 mice at the experimental endpoint. (A) T cell proliferation levels were measured after a
72-hour incubation period with and without the addition of ConA. An Alamar Blue assay was
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preformed and followed by measuring optical densities (OD) at 570 nm by spectrophotometry, to
quantify proliferation. (B) Proliferation index was calculated by dividing the average ODs of
stimulated by the average of non-stimulated ODs. Data presented as average ± SEM.
Immunophenotyping of splenocytes was done the same day (day 28) as cell counting and T
cell proliferation assays. Cell samples were stained with fluorochrome-labeled antibodies; each
antibody was responsible for staining a different cell type. The following cell types were
quantified: T cells (CD3+), T helper cells (CD4+), T cytotoxic cells (CD8+), T regulatory cells,
B cells (B220+), NK cells, and macrophages. There were no significant differences between the
control and SB treatment groups for any of the quantified cell types (Figure 4). Data were
successfully collected from 14 control (12/14 (86%) diabetic and 2/14 (14%) non-diabetic) and
13 SB-treated (8/13 (62%) diabetic and 5/13 (38%) non-diabetic) mice, acquired using a
FACSCalibur Flow Cytometer.
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Figure 4
Immunophenotypes in STZ-treated B6 Mice Treated with 200 mM SB
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Note. Immunophenotyping of splenocytes obtained from 200 mM SB-treated and control STZB6 mice on day 28 post the first STZ injection. Immunophenotypes presented as percentages.
Data presented as average ± SEM.

Cytokine samples were collected at the experimental endpoint after splenocytes were
cultured for 48 hours with the presence of ConA and analyzed. The following cytokines were
quantified: IL-2, IL-4, IL-6, IFN-γ, TNF, IL-17A, and IL-10. There were no significant
differences between control and SB treatment groups for any of the studied cytokines (Figure 5).
However, there were trends of decreased IL-6, IFN-gamma, and TNF-α.
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Figure 5
Cytokine Profiles in STZ-treated B6 Mice Treated with 200 mM SB
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Note. Cytokine profiles of splenocytes, obtained on day 28 post the first STZ injection in B6
mice treated with 200 mM SB and controls. Data presented as average ± SEM.

2. Effects of 20 mM Sodium Bicarbonate in a STZ-B6 mouse model
T1D Incidence and Glycemia Levels
After observing the positive effects of 200 mM SB treatment on diabetes incidence and
glycemia, we asked whether a ten times lower dose of SB would have similar effects. Thus, a
new set of experiments were performed in order to study the effects of a low dose (20 mM) of
SB on the same parameters in a low-dose STZ-induced experimental B6 model of T1D. Sevenweek-old B6 mice were treated with 20 mM SB or non-treated water. At eight-weeks of age,
T1D was induced via five injections of STZ. Blood glucose and body weight measurements were
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recorded on day -7 before, and biweekly from day 7 to day 28 post the first STZ injection.
Though there is a trend that suggests that 20 mM SB decreased T1D incidence and glycemia
levels, no significance was reached (Figure 6A and 6B). Overall, T1D incidence in control mice
was lower than expected for this model of T1D at the experimental endpoint; 67% of control
mice were diabetic in comparison to 42% in SB-treated group of mice.
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Figure 6
Diabetes Incidence and Glycemia in STZ-treated B6 Mice Treated with 20 mM SB
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Note. Diabetes incidence (A) and average glycemia (B) in STZ-B6 mice treated with 20 mM SB
for five weeks and their respective controls. (A) Diabetes incidence presented as the percentage
of diabetes-free mice in control and SB treatment groups. (B) Glycemia measurements were
taken at days -7, 7, 11, 14, 18, 21, 25, and 28 pre/post first STZ injections. Data presented as
average ± SEM.
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Body Weight, Cell Counts, and Cell Viability
Body weight measurements were taken in tandem with blood glucose measurements.
Mice were weighed once before STZ injections (day -7) and biweekly for three weeks after
(from day 7 to day 28). There was no significant difference observed between the average
body weight measurements when comparing 20 mM SB-treated and control mice (Figure
7A). Mice were sacrificed at day 28, spleens were harvested, and single cell suspensions
were prepared. A small portion of the cells were used to count the number of live and dead
cells in each sample, via hemocytometer. Those counts were then used to calculate cell
viability. There were no significant differences between cell counts and cell viability when
comparing 20 mM SB-treated and control B6 mice (Figure 7B and 7C). Out of 12 control
and 12 SB-treated mice analyzed at the end timepoint, there were 7 (58%) and 5 (42%)
diabetic mice, respectively (Figure 7B and 7C).
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Figure 7
Body Weights, Cell Counts, and Cell Viability in STZ-treated B6 Mice Treated with 20 mM SB
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Note. Average body weights (A), cell counts (B), and cell viability (C) in 20 mM SB-treated and
control STZ-B6 mice sacrificed at the experimental endpoint. (A) Body weight measurements
started on day -7 before the first STZ injection and lasted until the experimental endpoint. Data
presented as average ± SEM. (B) Cell counts were measured using the Trypan blue exclusion
method. Data presented as average ± SEM. (C) Cell viability was calculated using cell counts.
Data presented as average ± SEM.
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Immune Parameters
Ex vivo 20 mM SB experiments followed the same procedures as the 200 mM SB
experiments. Proliferation levels were measured by plating splenocytes in triplicates, with and
without the presence of ConA. After 72 hours, Alamar blue was added, and the plate was
analyzed using a spectrophotometer. There were no differences observed when comparing
proliferation levels of SB treatment and control groups, regardless of the presence of ConA or
lack thereof (Figure 8A). Although there was a trend towards decreased proliferation index in
SB-treated mice, there was no significant difference when comparing proliferation indexes of the
control and SB treatment groups (Figure 8B).
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Figure 8
Proliferation Levels and Proliferation Index in STZ-treated B6 Mice Treated with 20 mM SB
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Note. Proliferation levels (A) and proliferation index (B) in 20 mM SB-treated and control STZB6 mice at the experimental endpoint. (A) T cell proliferation levels were measured after a 72hour incubation period with and without the addition of ConA. An Alamar Blue assay was
preformed and followed by measuring optical densities (OD) at 570 nm by spectrophotometry, to
quantify proliferation. (B) Proliferation index was calculated by dividing the average ODs of
stimulated by the average of non-stimulated ODs. Data presented as average ± SEM.
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Quantification of immunophenotypes and cytokine profiles was done using a flow
cytometer. There were no statistical differences between control and SB treatment groups when
observing all analyzed cell types (Figure 9). CD8+ were not quantified, due to technical
difficulties. When observing the seven cytokine profiles targeted with the kit, there were no
significant differences between the control and 20 mM SB-treated B6 mice, but there were trends
towards decreased IL-6, IFN-γ, and TNF-α levels in 20 mM SB treatment mice (Figure 10).
Figure 9
Immunophenotypes in STZ-treated B6 Mice Treated with 20 mM SB
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Note. Immunophenotyping of splenocytes obtained on day 28 from 20 mM SB-treated and
control STZ-B6 mice. Immunophenotypes are presented as percentages. Data presented as
average ± SEM.
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Figure 10
Cytokine Profiles in STZ-treated B6 Mice Treated with 20 mM SB
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Note. Cytokine profiles of splenocytes obtained on day 28 from 20 mM SB-treated and control
STZ-B6 mice. Data presented as average ± SEM.

3. Effects of 200 mM Sodium Bicarbonate Treatment in a NOD mouse model
Incidence of T1D and Glycemia Levels
NOD mice are commonly used in T1D research because they develop T1D spontaneously
and over time, similar to humans; No STZ injections are needed for induction of disease. In this
set of experiments, 10-week-old NOD mice were administered 200 mM SB-treated water or nontreated water (control). At 12-weeks of age, weekly glycemia and body weight measurements
began and lasted until the experimental endpoint. Though trends suggested a decrease in both,
SB treatment did not exhibit any significant effects on T1D incidence or glycemia levels (Figures
11A and 11B). Whereas 50% of control mice became diabetic on week 17, mice administered
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with SB reached the same percentage later, on week 21. At the end of experimental period, there
were 70% of diabetic mice in the control group versus 60% in SB-treated group (Figure 11A).
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Figure 11
Diabetes Incidence and Glycemia in NOD Mice Treated with 200 mM SB at the Experimental
Endpoint
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Note. T1D incidence (A) and glycemia levels (B) in 200 mM SB-treated and control NOD mice
treated for 13 weeks. (A) Diabetes incidence presented as the percentage of diabetes free mice.
Diabetes was defined as two consecutive glucose readings of ≥ 250 mg/dL. (B) Glycemia
measurements were recorded weekly starting at 12-weeks of age and ending on the experimental
endpoint. Data presented as average ± SEM.
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Body Weight, Cell Counts, and Cell Viability
Body weight measurements were recorded weekly starting at 10-weeks of age until the
experimental endpoint. When observing body weight measurements, there was a significant
interaction between control and SB treatment groups (p=0.0193) (Figure 12A). Cell counts and
viability were done using the same methodology described in the STZ-B6 experiments. High
dose SB did not significantly affect cell counts or viability (Figures 12B and 12C). On the cell
counts and viability graphs, one can see a lower number of mice in comparison to the original
number of mice put in the experiment. This was due to high number of mice that developed
severe T1D symptoms before the experimental endpoint. The remaining five mice in each group
were diabetes free.
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Figure 12
Body Weights, Cell Counts, and Cell Viability in NOD Mice Treated with 200 mM SB at the
Experimental Endpoint
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Note. Average body weights (A), cell counts (B), and cell viability (C) in 200 mM SB-treated
and control NOD mice sacrificed at the experimental endpoint. (A) Body weight measurements
were recorded weekly starting at week 12 and lasted until the experimental endpoint. Data
presented as average ± SEM, *p<0.05 (B) Cell counts were measured using the Trypan blue
exclusion method. Data presented as average ± SEM. (C) Cell viability was calculated using cell
counts. Data presented as average ± SEM.
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Immune Parameters Observed at the Experimental Endpoint
In this set of experiments that are performed in NOD mice, proliferation levels,
proliferation index, immunophenotyping, and cytokine profiling were preformed following the
same methodology as already described for the experiments executed in STZ-B6 mouse model.
High dose SB did not significantly affect the proliferation levels, proliferation index, cell
subtypes, or cytokine profiles (Figure 13A, 13B, 14, and 15). However, several trends were
observed in SB-treated mice when compared to their controls, including decreased proliferation
index, IFN-γ, and IL-6 levels, as well as increased percentages of CD3+ T cells and CD4+ Th
cells.
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Figure 13
Proliferation Levels and Proliferation Index in NOD Mice Treated with 200 mM SB at the
Experimental Endpoint
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Note. Proliferation levels (A) and proliferation index (B) in 200 mM SB-treated and control
NOD mice at the experimental endpoint. (A) T cell proliferation levels were measured after a 72hour incubation period with and without the addition of ConA. An Alamar Blue assay was
preformed and followed by measuring optical densities (OD) at 570 nm by spectrophotometry, to
quantify proliferation. (B) Proliferation index was calculated by dividing the average ODs of
stimulated by the average of non-stimulated ODs. Data presented as average ± SEM.
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Figure 14
Immunophenotypes in NOD Mice Treated with 200 mM SB at the Experimental Endpoint
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Note. Immunophenotyping of splenocytes obtained at the experimental endpoint from 200 mM
SB-treated and control NOD mice. Immunophenotypes are presented as percentages. Data
presented as average ± SEM.
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Figure 15
Cytokine Profiles in NOD Mice Treated with 200 mM SB at the Experimental Endpoint
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Note. Cytokine profiles of splenocytes obtained at the experimental endpoint from 200 mM SBtreated and control NOD mice. Data presented as average ± SEM. This set of cytokines was
acquired using a FACSCalibur, which presented some technical difficulties in accurately reading
IL-2 levels.

T1D Incidence, Glycemia Levels, Body Weight, Cell Counts and Cell Viability at the
Early Timepoint
This set of experiments was done to investigate the effects of high dose SB before the
onset of disease. The same methodology was followed as in the long-term NOD experiments,
with the exception that the SB treatment lasted only five weeks. Thus, mice were euthanized, and
experimental parameters analyzed before expected start of obvious clinical symptoms
(hyperglycemia). Glycemia and body weight measurements were recorded weekly for the last
three weeks (week 12 to week 14) of treatment. High dose SB did not have a significant effect on
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body weights of NOD mice (Figure 16C). However, high dose SB was found to significantly
decrease glycemia levels in SB treatment group (p=0.0329) (Figure 16B). T1D incidence data
followed a similar trend with a decrease in diabetes development but was not significant (Figure
16A). Control and SB treatment groups had similar cell counts and viability; no statistically
significant differences were observed (Figures 16D and 16E). This set of short-term (5 weeks)
200 mM SB treatment experiment followed similar trends in diabetes incidence and glycemia
levels to the previously described long-term (~ 15 weeks) 200 mM SB experiment.
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Figure 16
Diabetes Incidence, Glycemia, Body Weights, Cell Counts, and Cell Viability in NOD Mice
Treated with 200 mM SB at the Early Experimental Endpoint
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Note. T1D incidence (A), glycemia levels (B), body weight (C), cell counts (D), and cell
viability (E) in 200 mM SB-treated and control NOD mice treated for five weeks. (A) Diabetes
incidence presented as the percentage of diabetes free mice. Diabetes was defined as two
consecutive glucose readings of ≥ 250 mg/dL. (B) Glycemia measurements were recorded
weekly starting at 12-weeks of age and ending on the experimental endpoint; data presented as
average ± SEM, *p<0.05 (C) Body weight measurements were recorded weekly starting at week
12 and lasted until the early experimental timepoint (14 weeks of age). Data presented as average
± SEM. (D) Cell counts were measured using the Trypan blue exclusion method. Data presented
as average ± SEM. (E) Cell viability was calculated by using cell counts. Data presented as
average ± SEM.
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Immune Parameters at the Early Experimental Timepoint
The following data are from NOD mice treated with 200 mM SB and their controls
euthanized at the early experimental timepoint (14 weeks of age). There were no significant
effects observed on T cell proliferation or proliferation index in 14-week-old NOD mice treated
with 200 mM SB (Figures 17A and 17B). However, a trend of increased proliferation in SBtreated mice, comparted to their respective controls, was observed. When observing the
proliferation assay graphs, out of 5 control and 8 SB-treated mice analyzed at the early timepoint, there were 3 (60%) and 1 (13%) diabetic mice, respectively (Figures 17A and 17B).
Immunophenotyping showed significant decreases in CD3+ and CD4+ populations (p=0.0188
and p=0.0401, respectively) and significant increases in B220+ and macrophage populations
(p=0.0233 and p=0.0050, respectively) in mice treated with 200 mM SB compared to their
controls (Figure 17C). Though no significance was reached, a trend toward decreasing CD8+
populations in SB-treated mice was observed. Immunophenotyping data were successfully
collected from 7 control [5 (71%) diabetic and 2 (29%) non-diabetic] and 7 SB-treated [0
diabetic and 7 (100%) non-diabetic] mice (Figure 17C). High dose SB did not have significant
effects on cytokine profiles, but there were trends indicating increases in IL-6, IFN-γ, and TNF
in 200 mM SB-treated mice compared to their controls (Figure 17D). Out of the 5 control and 4
SB-treated mice analyzed in cytokine profiling, there were 3 (60%) and 1 (25%) diabetic mice,
respectively (Figure 17D).
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Figure 17
Proliferation Levels, Proliferation Index, Immunophenotypes, and Cytokine Profiles in NOD
Mice Treated with 200 mM SB at the Early Experimental Endpoint
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Note. Proliferation levels (A), proliferation index (B), immunophenotypes (C), and cytokine
profiles (D) of 200 mM SB-treated and control NOD mice sacrificed at the early experimental
timepoint. (A) T cell proliferation levels were measured after a 72-hour incubation period with
and without the addition of ConA. An Alamar Blue assay was preformed and followed by
measuring optical densities (OD) at 570 nm by spectrophotometry, to quantify proliferation. (B)
Proliferation index was calculated by dividing the average ODs of stimulated by the average of
non-stimulated ODs. (C) Immunophenotyping of splenocytes obtained at the early experimental
timepoint from 200 mM SB-treated and control NOD mice. Immunophenotypes are presented as
percentages. Data presented as average ± SEM, *p<0.05 compared to own, respective control
group of mice for each particular cell type. (D) Cytokine profiles of splenocytes obtained at the
early experimental timepoint from 200 mM SB-treated and control NOD mice. Data presented as
average ± SEM.
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4. Effects of 20 mM Sodium Bicarbonate in a NOD Mouse Model
T1D Incidence and Glycemia Levels
The following data were obtained in NOD mice treated with 20 mM SB from their prediabetic age at 9 weeks and their controls until the experimental endpoint at 25-weeks of age.
Although significance was not reached, there was a trend of decreased T1D incidence and
glycemia levels in SB-treated NOD females (Figures 18A and 18B). Throughout the entire
experiment, 20 mM SB-treated mice had lower glycemia levels (p=0.0840). Whereas 50% of
control mice became diabetic at 17 weeks of age, mice administered with SB reached the same
percentage later, at 22 weeks of age. At the end of experimental period, there were 75% of
diabetic mice in the control group versus 50% in SB-treated group (figure 18A).
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Figure 18
Diabetes Incidence and Glycemia in NOD Mice Treated with 20 mM SB at the Experimental
Endpoint
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Note. T1D incidence (A) and glycemia levels (B) in 20 mM SB-treated and control NOD mice
treated for 15 weeks. (A) Diabetes incidence presented as the percentage of diabetes free mice.
Diabetes was defined as two consecutive glucose readings of ≥ 250 mg/dL. (B) Glycemia
measurements were recorded weekly starting at 14-weeks of age and ending on the experimental
endpoint. Data presented as average ± SEM.
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Body Weight, Cell Counts, and Cell Viability
The following body weight data are obtained from NOD mice treated with 20 mM SB
and water from 9 until 25 weeks of age. At the experimental endpoint mice were euthanized and
splenocyte counts and viability determined. There were no significant differences in 20 mM SBtreated mice and control mice when observing body weight measurements, cell counts, and cell
viability (Figure 19A, 19B, and 19C). On the graphs showing cell counts and viability, one can
see a lower number of examined mice in comparison to the original number of mice put in the
experiment. This was due to high number of mice that developed prominent T1D symptoms
before the experimental endpoint. Of the remaining 3 control and 7 SB-treated mice at the
experimental endpoint, there were 1 (33%) and 2 (29%) diabetic mice, respectively (Figures 19B
and 19C).
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Figure 19
Body Weights, Cell Counts, and Cell Viability in NOD Mice Treated with 20 mM SB at the
Experimental Endpoint
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Note. Average body weights (A), cell counts (B), and cell viability (C) in 20 mM SB-treated and
control NOD mice sacrificed at the experimental endpoint. (A) Body weight measurements were
recorded weekly starting at week 14 and lasted until the experimental endpoint. Data presented
as average ± SEM. (B) Cell counts were measured using the Trypan blue exclusion method. Data
presented as average ± SEM. (C) Cell viability was calculated using cell counts. Data presented
as average ± SEM.
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Immune Parameters Observed at the Experimental Endpoint
At the experimental endpoint splenic cells were analyzed for their proliferative capacity.
Low-dose SB significantly decreased ConA-stimulated proliferation level presented as a raw
optical density value (p=0.0157) and exhibited a trend of decreased proliferation index compared
to their controls (Figures 20A and 20B). Low-dose SB did not show significant effects on
immune cell subpopulations or cytokine profiles (Figures 21 and 22). However, a trend of
decreased IFN-γ was observed.
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Figure 20
Proliferation Levels and Proliferation Index in NOD Mice Treated with 20 mM SB at the
Experimental Endpoint
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Note. Proliferation levels (A) and proliferation index (B) in 20 mM SB-treated and control NOD
mice at the experimental endpoint. (A) T cell proliferation levels were measured after a 72-hour
incubation period with and without the addition of ConA. An Alamar Blue assay was preformed
and followed by measuring optical densities (OD) at 570 nm by spectrophotometry, to quantify
proliferation. (B) Proliferation index was calculated by dividing the average ODs of stimulated
by the average of non-stimulated ODs. Data presented as average ± SEM, *p<0.05.
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Figure 21
Immunophenotypes in NOD Mice Treated with 20 mM SB at the Experimental Endpoint
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Note. Immunophenotyping of splenocytes obtained at the experimental endpoint from 20 mM
SB-treated and control NOD mice. Immunophenotypes are presented as percentages. Data
presented as average ± SEM.

Figure 22
Cytokine Profiles in NOD Mice Treated with 20 mM SB at the Experimental Endpoint
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Note. Cytokine profiles of splenocytes obtained at the experimental endpoint from 20 mM SBtreated and control NOD mice. Data presented as average ± SEM.
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T1D Incidence, Glycemia Levels, Body Weight, Cell Counts and Cell Viability at the Early
Timepoint
This set of experiments was done to draw conclusions on the effects of 20 mM SB
administration in pre-diabetic or recently diabetic NOD mice treated from 9 to 14 weeks of age.
Glycemia and body weight measurements were recorded weekly, from 12 to 14 weeks of age.
On week 12, glycemia levels were similar between SB treatment (168 ± 42 mg/dL) and control
(156 ± 33 mg/dL) groups, while on week 14, the average glycemia for the SB treatment group
was 207 ± 57 mg/dL and the control average was 111 ± 1 mg/dL. Glycemia levels, as well as
T1D incidence did not significantly differ between the SB-treated and control mice. There were
2/15 (87%) and 2/16 (87.5%) diabetic mice in 14-week-old SB-treated and control mice,
respectively. There were also no significant differences in average body weights between
control and SB treatment groups (data not shown). When observing cell counts and viability of
20 mM SB-treated and control NOD mice euthanized at 14 weeks of age post 5 weeks of
treatment, no significant differences were observed (Figures 23A and 23B).
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Figure 23
Cell Counts and Cell Viability in NOD Mice Treated with 20 mM SB at the Early Experimental
Endpoint
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Note. Average cell counts (A), and cell viability (B) in 20 mM SB-treated and control NOD mice
at the early experimental timepoint. (A) Cell counts were measured using the Trypan blue
exclusion method. Data presented as average ± SEM. (B) Cell viability was calculated by using
cell counts. Data presented as average ± SEM.
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Immune Parameters Observed at the Early Timepoint
The following data were collected from 20 mM SB-treated and control NOD mice at the
early experimental timepoint, at 14 weeks of age. Though there was a trend of increased
proliferation index in SB-treated mice, low dose SB treatment did not have a significant effect on
T cell proliferation or proliferation index (Figures 24A and 24B). However, 20 mM SB treatment
did significantly increase CD3+ T cells and NK cells (p=0.0333 and p=0.0052, respectively);
while B220+ cells were significantly decreased (p=0.0099), compared to controls (Figure 24C).
Cytokine measurements showed a significant increase in IFN-γ (p=0.0435) (Figure 24D).
Although not significant, there was a trend of increased IL-6 and TNF-α in SB-treated mice
when compared to control mice.
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Figure 24
Proliferation Levels, Proliferation Index, Immunophenotypes, and Cytokine Profiles in NOD
Mice Treated with 20 mM SB at the Early Experimental Endpoint
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Note. Proliferation levels (A), proliferation index (B), Immunophenotypes (C), and cytokine
profiles (D) of 20 mM SB-treated and control NOD mice at an early experimental timepoint. (A)
T cell proliferation levels were measured after a 72-hour incubation period with and without the
addition of ConA. An Alamar Blue assay was preformed and followed by measuring optical
densities (OD) at 570 nm by spectrophotometry, to quantify proliferation. (B) Proliferation index
was calculated by dividing the average ODs of stimulated by the average of non-stimulated ODs.
(C) Immunophenotyping of splenocytes obtained at the early experimental timepoint from 20
mM SB-treated and control NOD mice. Immunophenotypes are presented as percentages; data
presented as average ± SEM, *p<0.05 compared to own, respective control group of mice for
particular cell type. (D) Cytokine profiles of splenocytes obtained at the early experimental
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timepoint from 20 mM SB-treated and control NOD mice; data presented as average ± SEM,
*p<0.05 compared to own, respective control group of mice for each particular cytokine.
VI: Summary
•

High-dose SB treatment exhibited antidiabetic property, decreasing disease incidence in
STZ-B6 model of T1D, whereas the same effect was not achieved in NOD mice, besides
the transient lowering of glycemia.

•

SB treatment did not induce obvious toxic effects either systemically or on the immune
organs, such as spleen, and its immune cells in both mouse models of T1D.

•

SB treatments, both high- and low-dose, did not prominently affect T cell composition
and function, besides observed trends in lowering T cell proliferation and
proinflammatory cytokines in a STZ-B6 model.

•

SB treatments, both high- and low-dose, did not prominently affect T cell proliferation,
composition, and cytokines, besides the trends in lowering proliferation and
proinflammatory cytokines at the endpoint of investigation in NOD mice.

•

Interestingly, SB treatments, both high- and low-dose, did prominently affect T cell
composition, by decreasing or increasing T /Th cells (dependent on the SB dose), and
increase proinflammatory cytokines, especially IFN-γ at the early time point during the
development of T1D in NOD mice.
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Table 2
In Vivo Results Summary

Note. Summary of results from in vivo experiments. A large arrow represents a significant
increase or a significant decrease in the SB-treated group versus the respective control group
(*p<0.05). A small arrow represents trends within the data. An up arrow insinuates an increased
trend in the SB-treated group versus the respective control group. A down arrow insinuates a
decreased trend in the SB-treated group versus the respective control group. A dashed line
represents data that did not exhibit any difference between the SB treatment and control groups.
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Table 3
Ex Vivo Results Summary

Note. Summary of results from ex vivo experiments. A large arrow represents a significant
increase or a significant decrease in the SB-treated group versus the respective control group
(*p<0.05). A small arrow represents trends within the data. An up arrow insinuates an increased
trend in the SB-treated group versus the respective control group. A down arrow insinuates a
decreased trend in SB-treated group versus the respective control group. A dashed line represents
data that did not exhibit any difference between the SB treatment and control groups.
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VII: Discussion
Effects of SB treatment on Body Weight, Cell Counts, and Cell Viability
The first question that came to mind when we chose to perform SB experiments was
whether chronic administration of oral SB could cause health complications. High levels of
sodium bicarbonate are known to increase pH levels in the blood, which can lead to metabolic
alkalosis, but can also cause hypernatremia, hypertension, and other serious health complications
(NCBI, 2020a). There are several case studies focusing on the toxicity of chronic consumption of
SB; however, patients in most of these studies misused sodium bicarbonate by taking a higher
than recommended dose (Al-Abri & Olson, 2013; Hughes, Brown, & Valento, 2016). In early
experiments, mice we treated with 200 mM SB. This dose has been used in mice and in rats to
treat diseases such as polycystic kidney disease, and cancer, for 21 weeks (Robey et al., 2009),
and 8.5 weeks (Torres, Cowley, Branden, Yoshida, & Gattone, 2001), respectively. Through
several analyses, including pH testing, body weight measurements, and urinalysis, these papers
confirmed that chronic consumption of 200 mM does not cause significant changes in systemic
pH, nor does it induce metabolic alkalosis in mice or rats. In comparison to the length of 200
mM SB treatment evaluated in these studies, our experimental design implemented 5 and 15
weeks of SB administration in STZ-induced, and NOD mouse models of T1D, respectively.
After 200 mM SB treatment was initiated, we closely observed the mice for any
behavioral or physical changes. There were no obvious behavior or physical differences between
the SB-treated and control mice. We also took body weight measurements, weekly or biweekly,
depending on the experimental design and the mouse model, throughout the duration of each
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experiment to ensure that SB treatment mice was not prominently changing their weight. A
significant change of weight could indicate potentially harmful pathological effects of the
treatment. We did not see prominent weight fluctuations in any of the experimental groups.
However, there was a significant interaction between the average body weights in 200 mM SBtreated and control groups followed until 23 weeks of age. Another indication of harmful
treatment-related effects would be differences in splenic cell counts and viability between the
control and treatment mice. At the end of experimental period or at the early time points, mice
were euthanized, spleens were harvested, single cell suspensions prepared, and cells evaluated
for their numbers and viability. If SB treatment was inducing toxic effects, one might expect to
observe a decreased number of splenocytes or decreased splenocyte viability. However, in our
experiments, we observed neither. Thus, we concluded that 200 mM SB does not exhibit toxic
effects during a long-term administration period of 5 and 15 weeks in STZ-B6 or NOD mice,
respectively.
Effects of SB treatment on T1D Incidence and Glycemia Levels
Throughout the study, we devised and utilized methods that could be easily translated
from mice to humans. As described in literature, SB treatment in B6 mice began before T1D
induction via STZ injections (Cetkovic-Cvrlje, Thinamany, & Bruner., 2017). Such a
pretreatment allows mimicking of how a particular compound would interfere with T1D
development in humans before the onset of beta cell destruction and T1D onset. SB was given
orally, via drinking water, because that is the most feasible way to administer this compound to
humans. In general, oral administration is favored in literature because it allows for more
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absorption to occur through the mucosal cells within the mouth (Le, 2020). Other methods of
medication administration, including gavage and injections, can cause research animals
unwarranted stress and pain, which, in turn, can have adverse effects on the physiological levels
of blood glucose (Zhang, 2011).
In our firstly performed experiments, STZ-B6 mice were treated with 200 mM SB ad
libitum. This dose has been administered to mice and rats in several studies on diseases such as
cancer and polycystic kidney disease (Robey et al., 2009; Torres et al., 2001). However, the
effects of SB have never been studied in autoimmunity. In 2018, Ray et al. published an article
on sodium bicarbonate and its anti-inflammatory potential, which initiated speculation on
whether SB could be used to treat an autoimmune inflammatory disease, such as T1D. There are
several parameters that can collectively inform whether SB expresses an antidiabetic potential,
one being glycemia. It is crucial to observe the timing of rising glycemia level during
development of experimental T1D, as well as its level. In the 200 mM SB-treated STZ-B6 mice,
we observed a significant decrease in T1D incidence and a trend of lower glycemia levels
throughout the entire duration of the experiment. Since the antidiabetic property of the 200 mM
SB treatment was observed, it was further questioned whether a lower dose of SB might exhibit
similar effects. Hence, in our second set of experiments the STZ-B6 mice were treated with 20
mM SB. While there were observed trends in lowering both T1D incidence and glycemia levels,
treatment with 20 mM SB did not result with a statistically significant difference compared to
controls.
Even though the results from the SB experiments, especially high-dose SB treatment,
using the STZ-induced model of T1D in B6 mice were favorable, it was still desirable to
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evaluate both doses of SB in NOD mouse model of autoimmune T1D. STZ-treated B6 mice and
NOD mice are both valuable models for T1D, but they give different insights into the disease.
While the cause of T1D has not been completely elucidated, researchers have concluded that
T1D etiopathogenesis is associated with both genetics and the environmental triggers (Knip &
Simell, 2012). STZ-treated B6 mice serve as the environmentally related T1D mouse model,
because injection of a toxin is required to slightly destroy and modify beta cell antigenicity and
induce disease development. In contrast, NOD mice spontaneously develop diabetes because of
the genetic predisposition; thus, the environmental influences are secondary. They are favored
throughout literature because they develop T1D most similarly to humans (Punt et al., 2019).
Several experiments were performed to test the effects of both 20 mM and 200 mM SB on T1D
development in NOD mice during the 15 weeks, from their pre-diabetic age of 9 weeks to 24±1
weeks of age when the majority of NOD females, depends on the colony, should develop
symptoms of obvious diabetes. Although not statistically significant, a trend of decreased T1D
and glycemia levels was observed in NOD mice that were administered 200 mM and 20 mM SB
for 15 weeks, compared to their respective controls. A similar trend of decreased T1D incidence
was observed, as well as significantly decreased glycemia levels, in 200 mM SB-treated NOD
mice at the early experimental timepoint (14-week-old) when compared to the control group.
Overall, one can conclude that SB exhibited the most prominent antidiabetic effect while used in
a dose of 200 mM in reducing the T1D incidence in STZ-induced B6 model, and in reduction of
glycemia levels in NOD mice that were sacrificed at the early timepoint.
The prominent antidiabetic property of 200 mM SB treatment that was observed in the
STZ-B6 mouse model may be related to method of T1D induction in B6 mice. As SB treatment
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has the potential to increase bicarbonate concentration, changing the pH in the islet
microenvironment of B6 mouse that are going to be injected by STZ, could potentially lead to
anti-diabetic effects. To induce T1D in a B6 mouse model, a low-dose STZ is prepared in
sodium citrate buffer at a pH of 4.5, to stabilize the toxin (Sviglerova, Kuncova, & Stengl, 2013).
Many studies have claimed that a buffer pH of 4.0-4.5 is crucial for STZ action on beta cells
(Povoski, McCullough, Zhou, & Bell, 1993; Gurley et al., 2006; Weide & Lacy, 1991). Lowdose STZ injections produce beta cell destruction gradually; if SB treatment altered the pH of the
STZ solution, SB could have diminished/prolonged the STZ destructive power on beta cells.
However, contrasting literature stated that a buffer pH of 4.0-4.5 is not necessary to stabilize
STZ and a neutral pH of 7.4 would produce similar stability for up to one hour (Lenzen, 2008).
Effects of SB Treatment on Immune Parameters
Though several papers have proposed anti-inflammatory effects of SB, this is the first
ever study on the effects of SB in an autoimmune disease, T1D specifically (Torres, Mujwid,
Wilson, & Holley, 1994; Ray et al., 2018). To draw conclusions on the effects of SB treatment
on T cell-dependent T1D, we studied several T cell-associated immune parameters, including T
cell proliferation, immunophenotypes, and cytokine profiles. We tested these parameters in both
STZ-induced B6 and NOD mouse models at several timepoints.
Proliferation levels of T cells give an insight into the functionality of T cells. The
proliferation results obtained in both STZ-induced B6 and NOD models, while overall not
reaching the statistical significance, followed similar trends. All ConA-stimulated splenic
samples, obtained from 200 mM SB-treated mice exhibited a trend of decreased proliferation
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levels when compared to their respective control groups. It is worth noticing that in the 200 mM
SB experiments, at the experimental endpoint, all living mice (5 control and 5 SB-treated) were
not diabetic. Usually, the problem with that endpoint is that the majority of living mice became
diabetic and that hyperglycemia per se can potentially skew immunologic parameters, such as T
cell proliferation, composition, and cytokines. However, in this particular experiment, the
influence of hyperglycemia can be ruled out as all the control and SB-treated mice were
normoglycemic. In the 20 mM SB experiments, at the experimental endpoint, several of the
remaining mice were non-diabetic (1 out of 3 control (33.3%) and 5 out of 7 (71%) SB-treated
mice were not diabetic). Previous literature stated the high levels of blood glucose can induce
suppression of T cell proliferation, which can occur due to increased cellular adenosine outflow.
(Sakowicz-Burkiewicz, Kocbuch, Grden, Szutowicz, & Pawelczyk, 2006). However, Uhl et al.
(2020) stated that the administration of bicarbonate in acidic conditions enhanced T cell function.
There were no significant differences between control and SB treatment groups when
looking at immunophenotyping and cytokine profile data in STZ-induced B6 mice. However,
there were trends observed in reduced IL-6, TNF, and IFN-γ cytokine levels in 20 mM and 200
mM SB-treated B6 mice compared to their respective controls. Also, at the experimental
endpoint (24±1 wk. old), high- and low-dose SB-treated NOD mice exhibited a non-significant
decrease in pro-inflammatory cytokines, IL-6, TNF-α, and IFN-γ. Though not significant, these
results indicate a slight reduction in the inflammatory action of T cells in a STZ model of T1D.
Some studies have suggested an increase of IFN-γ and TNF-α after 200 mM SB treatment (Uhl
et al., 2020; Kawakami, Koike, Maehara, Hayashi, & Fujimori, 2020), while others found an SB-

88
induced decrease in the aforementioned pro-inflammatory cytokines (Netea, Kullberg, Blok,
Netea, & Van der Meer, 1997). In the study published by Uhl et al., the effects of metabolic
reprogramming in T cells were studied in leukemic B6 mice (2020). They hypothesized that SB
administration would counteract acidosis in leukemia patients, leading to enhanced metabolic
fitness and T cell function. For two weeks, B6 mice were administered 200 mM SB. Flow
cytometry was used to conclude that acute 200 mM SB treatment increased T cell proliferation
as well as IFN-γ and TNF-α levels (Uhl et al., 2020). In another article, published in 2016,
researchers studied the effects of 200 mM SB treatment on tumor acidity to improve
immunotherapies (Pilon-Thomas, 2016). The study observed both the in vitro and in vivo effects
of SB in B6 mice. In vitro experiments focused on the effects of acidic or alkaline conditions on
T cells. Cell culture analyses lead to the conclusion that acidic environments have
immunosuppressive effects through a significant depletion in IFN-γ and TNF-α production in
alkaline conditions. Using flow cytometry, in vivo studies suggested that 200 mM SB treatment
significantly increased CD8+ T cells. Though CD8+ T cells are typically part of the proinflammatory immune response, these results suggest that alkaline environments have the
potential to promote immune responses in general (Pilon-Thomas, 2016).
Previous studies have described increased T cell function during pre-symptomatic and
early symptomatic stages of T1D development (Ekman et al., 2019; Roep, 2003) Thus, we found
it to be crucial to look at T cell function and subpopulation levels before T1D had completely
developed in NOD mice. In our latest experiments, we treated NOD mice with high and low dose
SB and harvested their spleens for cellular analysis at 14-weeks of age. At the early experimental
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timepoints, immunophenotyping showed contradictory data between low- and high-dose
treatments. High-dose SB caused significant decreases in CD3 and CD4 populations, and a
significant increase in the B220 population. While low dose SB treatment caused significant
increases in CD3, NK, and macrophage populations and a significant decrease in B220 cells.
Though immunophenotyping data seemed to be somewhat contradicting between these groups,
their cytokine profiles showed similar trends; there were increased levels of IL-6, TNF-α, and
IFN-γ, in both 20 mM and 200 mM SB-treated mice compared to their respective controls.
Many of the results obtained from STZ-B6 and NOD immunophenotyping and cytokine
profiling experiments were insignificant, contradicting, or both. We were not able to draw
consistent conclusions on SB’s effects on T cells in the context of T1D, but it was clear that SB
was having a beneficial effect on the reduction of glycemia levels and T1D incidence. Though
T1D is a T cell mediated disease, other immune cells are also involved in disease development.
In 2018, Ray et al. published that SB had anti-inflammatory effects in the spleen through its
action on macrophages. Using flow cytometry, the research team confirmed significant
polarization from M1 (inflammatory) to M2 (anti-inflammatory) macrophages in the kidneys and
spleens of rats (Ray et al., 2018). To do so, cells were stained with the following fluorochrometagged antibody mixtures: CD11b, CD68, and TNF-α (for M1 macrophages); CD11b, CD68,
CD206 and IL-10 (for M2 macrophages). The main focus of our project was to determine the
effects of SB on T cells in the context of T1D. Thus, most of the cell subtypes and cytokines
studied were T cell related. However, we did stain our samples with CD11b antibodies, which
stain most types of macrophages. This staining allowed us to draw conclusions about the effects
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of SB on total macrophage population, but not permitting to observe the effects of SB on
macrophage subtypes.
In the future it would be interesting to collect data regarding the extra- and intracellular
pH of T cells collected from our SB-treated and control mice. Those data could be helpful in
making connections between the potentially alkaline environment produced by SB treatment and
observed decreases in T1D incidence and glycemia levels in SB-treated mice. It would also be
insightful to measure levels of sodium (Na+) and bicarbonate (HCO-) in the blood of SB-treated
and control mice.
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VIII: Conclusion
High-dose SB treatment showed antidiabetic properties in STZ-induced model of T1D,
without a prominent effect observed in NOD mice. T cells do not appear to be the target of SB
action, since their composition and function was not markedly affected in both T1D models,
besides the transient changes observed at the early timepoint during the development of T1D in
NOD mice. Overall, our results, while promising, do not support SB as a major player in
preventative efforts in the fight against T1D.
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